Printer Friendly

GYNEX RECEIVES FDA APPROVAL OF TREATMENT IND FOR USE OF OXANDRIN(TM) IN GROWTH DISORDER

 GYNEX RECEIVES FDA APPROVAL OF TREATMENT IND
 FOR USE OF OXANDRIN(TM) IN GROWTH DISORDER
 VERNON HILLS, Ill., Nov. 10 /PRNewswire/ -- Gynex Pharmaceuticals, Inc. (NASDAQ: GYNX) today announced it received approval of a Treatment IND (Investigational New Drug application) from the U.S. Food and Drug Administration (FDA) for using Oxandrin (oxandrolone) to treat Turner syndrome, a genetic disorder in females that causes short height and lack of sexual development. There currently is no approved treatment for Turner syndrome.
 Gynex already holds a Treatment IND for Oxandrin in treating constitutional delay of growth and puberty, a growth disorder in boys.
 Treatment IND Allows Gynex To Recover Development,
 Distribution Costs
 "The Treatment IND process is designed to make significant potential therapies for serious conditions available to patients before clinical trials are completed," explained Stephen M. Simes, Gynex president. "This will allow Gynex to charge for the drug in order to recover the cost of research, production, and distribution when supplied to patients with Turner syndrome. In a few weeks, we expect to announce when Oxandrin will become available on a cost recovery basis."
 Number of Other Uses for Oxandrin
 Simes noted this Treatment IND represents another step in developing Oxandrin for a variety of conditions. Oxandrin is in human clinical trials for the treatment of AIDS patients suffering from HIV wasting syndrome and HIV associated muscle weakness. The company also plans to submit NDAs for use of Oxandrin in treating constitutional delay of growth and puberty and Turner syndrome as clinical trials are completed, beginning in 1993.
 Turner syndrome occurs when a girl is born with only one healthy X chromosome, compared with the two present in normal females. This condition results in short stature, non-functioning ovaries, and failure to develop secondary sexual characteristics. Published medical reports suggest that Oxandrin, alone or in combination with growth hormone, may significantly improve the rate of growth of Turner syndrome patients.
 Gynex Pharmaceuticals, Inc. develops and markets products for use in endocrinology, urology, metabolism, AIDS and gynecology.
 -0- 11/10/92
 /CONTACT: Stephen M. Simes of Gynex, 708-913-1144, or Lynne Franklin of Financial Relations Board, 312-266-7800, for Gynex/
 (GYNX) CO: Gynex Pharmaceuticals, Inc. ST: Illinois IN: MTC SU:


TS -- NY055 -- 9237 11/10/92 11:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1992
Words:373
Previous Article:JIM MANZI TO SPEAK AT MASSACHUSETTS COMPUTER SOFTWARE COUNCIL FALL MEMBERSHIP MEETING
Next Article:WANG SAYS FIRST QUARTER REVENUE MEETS PROJECTIONS; NOTIFIES SEC OF PLANS TO FILE FY '92 FINANCIAL STATEMENTS, MOVES ANNUAL MEETING DATE
Topics:


Related Articles
GYNEX BEGINS AIDS PATIENT TESTING OF POTENTIAL NEW DRUG THERAPY
GYNEX BEGINS PHASE III TRIAL OF POTENTIAL NEW TESTOSTERONE THERAPY
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF ATOVAQOUNE AS TREATMENT FOR PCP
GYNEX PHARMACEUTICALS ANNOUNCES FIRST ORAL DRUG FOR TURNER SYNDROME
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN REGULATORY APPROVAL FOR AGRELIN(R) TREATMENT IND
GYNEX DRUG CUTS DEATH RATE IN ALCOHOLIC HEPATITIS STUDY; GYNEX PLANS TO INCLUDE RESULTS IN FDA SUBMISSION BY THE END OF 1993
GUILFORD PHARMACEUTICALS RECEIVES CLEARANCE FOR GLIADEL TREATMENT IND
GUILFORD PHARMACEUTICALS FILES TREATMENT IND FOR GLIADEL
ARES-SERONO REAFFIRMS COMMITMENT TO OBTAIN APPROVAL FOR SEROSTIM FOR TREATMENT OF AIDS WASTING
Kiadis Pharma Obtains FDA Approval to Start a Phase III Clinical Trial for Reviroc(TM) in the United States.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters